References
- Zhang SR, Salup RR, Urias PE et al. Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 2. Cancer Immunol. Immunother.21, 19–25 (1986).
- Zhu X, Nishimura F, Sasaki K et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J. Transl. Med.5, 10 (2007).
- Wong JP, Christopher ME, Salazar AM, Dale RM, Sun LQ, Wang M. Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses. Vaccine25, 3175–3178 (2007).
- Wong JP, Nagata LP, Christopher ME, Salazar AM, Dale RM. Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs. Vaccine23, 2266–2268 (2005).
- de Jong JC, Claas EC, Osterhaus AD, Webster RG, Lim WL. A pandemic warning? Nature389, 554 (1997).
- Hatta M, Hatta Y, Kim JH et al. Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice. PLoS Pathog.3, 1374–1379 (2007).
- Maines TR, Lu XH, Erb SM et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J. Virol.79, 11788–11800 (2005).
- Keawcharoen J, van Riel D, van Amerongen G et al. Wild ducks as long-distance vectors of highly pathogenic avian influenza virus (H5N1). Emerg. Infect. Dis.14, 600–607 (2008).
- Baras B, Stittelaar KJ, Simon JH et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE3, E1401 (2008).